Physician profile
Deval Desai
NPI 1013446327
$2,213.71
in general payments reported to CMS, 2019-2025
14 companies · $453 in 2025
The $453 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $93.39 · 2021: $690 · 2022: $603 · 2023: $307 · 2024: $67.17 · 2025: $453.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $691 · Education: $136.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $691.15 |
| Education | $136.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,267.28 | 2021-2025 | Aveir, Ensite, Jot Dx |
| Biotronik INC. | $240.16 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $194.04 | 2025 | Camzyos, Eliquis |
| Boston Scientific Corporation | $177.03 | 2019-2025 | Watchman Flx |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $146.02 | 2021-2025 | Lifevest |
| Medtronic, INC. | $34.14 | 2025 | Azure Xt Dr Mri Surescan |
| Atricure, INC. | $25.24 | 2022 | |
| Pfizer INC. | $21.20 | 2025 | |
| Alnylam Pharmaceuticals INC. | $21.14 | 2024 | Onpattro |
| Siemens Medical Solutions USA, INC. | $20.22 | 2024 | Acuson Origin Diagnostic Ultrasound System |
| Scpharmaceuticals INC. | $20.05 | 2025 | |
| Novartis Pharmaceuticals Corporation | $17.76 | 2025 | |
| Heartflow, INC. | $15.17 | 2025 | |
| Esperion Therapeutics, INC. | $14.26 | 2025 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deval Desai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.